Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review

Antonino Grassadonia1,2, Marta Caporale2, Nicola Tinari1,2, Marinella Zilli2, Michele DeTursi1,2, Teresa Gamucci3, Patrizia Vici4, Clara Natoli1,2 on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia)

1. Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy
2. Medical Oncology Unit, “SS. Annunziata” Hospital, Chieti, Italy
3. Department of Oncology, “S.S. Trinita’” Hospital, Sora, Italy
4. Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy

Corresponding author: Antonino Grassadonia, email: grassadonia@unich.it, telephone +39 0871 3556732, fax +39 0871 3556707

Abstract

Inhibition of aberrantly activated pathways cross-talking with hormone receptor (HR) improves response to endocrine therapy in patients with HR-positive advanced breast cancer. We performed a Pubmed database systematic review to ascertain the existence of a better clinical response when combining endocrine therapy with targeted agents in the neoadjuvant setting. Preclinical studies or trials evaluating toxicity were excluded.

We found nine phase II trials that fulfilled the research criteria. The endocrine agents used were third generation aromatase inhibitors (AIs), anastrozole, letrozole or exemestane. The investigated targeted agents were inhibitors of tyrosine kinase receptors such as gefitinib, imatinib or trastuzumab/lapatinib, inhibitors of mTOR, such as everolimus, inhibitors of COX-2, such as celecoxib, and inhibitors of angiogenesis, such as bevacizumab. The response rate (RR) observed combining endocrine and targeted agents ranged between 36% and 90%.

Overall the studies failed to show a remarkable advantage in RR in the combination group compared to historical control subjects receiving AIs alone.

Key words: breast cancer; neoadjuvant endocrine therapy; targeted therapy; clinical response

Introduction

Neoadjuvant systemic therapy is strategically used to reduce the primary breast cancer volume and allow either surgery in patients initially judged inoperable [1-3], or conservative surgery in patients who otherwise would have received mastectomy [3, 4-6].

Long-term outcomes of pre- and post-operative therapy are comparable [4, 7-9], but the neoadjuvant approach gives additional information on the antitumor activity of the therapeutic agents and provides a precious biological system, the tumor itself, to study “in vivo” the possible mechanisms involved in the occurrence of resistance. Moreover, patients who achieve a pathologic complete response (pCR) after neoadjuvant treatment, i.e. absence of cancer in breast and nodes, have a very good prognosis [10, 11]. In this scenario, chemotherapy is usually the first choice of treatment for its ability to reach higher rates of pCR, while endocrine therapy is usually reserved for elderly patients with hormone receptor (HR)-positive tumors and affected by comorbidities.
Nevertheless, in recent years, neoadjuvant endocrine therapy is increasingly used as primary systemic therapy for postmenopausal women with HR-positive tumors given that this subgroup of patients achieves a low rate of pCR with chemotherapy and maintains, in any case, a favourable long-term outcome [12-16]. In addition, no prognostic advantage from the attainment of pCR has been observed in patients with HR-positive tumors [17].

In the neoadjuvant setting, tamoxifen has historically been employed, but the third generation aromatase inhibitors (AIs), including letrozole, anastrozole and exemestane, have been shown to be significantly superior to tamoxifen in terms of overall response rate (RR) and achievement of breast-conserving surgery [18-21].

As for other anti-cancer treatment, tumor might exhibit de novo or acquired resistance to endocrine therapy. The underlying mechanisms are not completely understood, but a major role seems to be played by cross-talks between HR and intracellular signaling triggered by tyrosine kinase receptors (TKRs) [22, 23]. The activation of these molecular pathways might affect tumor response to endocrine therapy. In fact, in preclinical studies, the overexpression of human epidermal growth factor receptor 2 (HER2) in tumor cells significantly reduces the activity of endocrine therapies [24-26]. Similarly, the epidermal growth factor receptor (EGFR) has been associated with endocrine-resistant phenotype [27], and platelet-derived growth factor receptor (PDGFR) has been shown to be associated with biological aggressiveness of breast cancer [28]. Among the downstream pathways activated by TKRs, the phosphoinositide-3-kinase (PI3K)/Akt signaling pathway, including the mammalian target of rapamycin (mTOR), has been showed to be involved in the resistance of breast cancer cells to endocrine therapy [29, 30]. Moreover, tumor cells might secrete pro-angiogenic factors, such as the vascular endothelial growth factor (VEGF), that in some way could limit hormone therapy efficacy. For example, in animal models the overexpression of VEGF in tumor cells is responsible for tamoxifen resistance [31]. In this altered molecular milieu the inhibition of a driver pathway by specifically designed agents (targeted agents) can restore hormone sensitivity [32-34].

Notably, in some cases, the preclinical research has been translated into clinical practice after confirmatory phase III clinical trials. In particular, the combination of an AI with anti-HER2 drugs, such as trastuzumab or lapatinib, has been demonstrated to achieve longer progression free survival compared to AI alone in postmenopausal women with metastatic HER2-positive breast cancer [35, 36]. In another study, the Bolero-2 trial, the combination of everolimus, a mTOR inhibitor, and exemestane resulted in an increased efficacy compared to exemestane alone in patients with HER2-negative advanced breast cancer who progressed to non-steroidal AI [37].

Differently from the metastatic setting, the neoadjuvant setting is a unique opportunity to assess the relative endocrine sensitivity of a tumor never exposed to a previous hormonal treatment and, therefore, might provide insights on the molecular mechanisms involved on the early occurrence of resistance.

The strong rationale and the clinically established benefit of adding a targeted agent to endocrine therapy in metastatic breast cancer prompted us to carry out a systematic review to evaluate a possible advantage of the combination also in the neoadjuvant setting, where a tumor shrinkage is often required to avoid mastectomy.

Methods

Study Selection

A search of PubMed database on studies combining endocrine therapy with targeted agents in the neoadjuvant setting of breast cancer and published from November 2004 to November 2014 was performed. To limit the research to articles that fulfilled the criteria of “neoadjuvant”, “endocrine therapy” and “clinical trials” we used the sorting key words according to the following algorithm: “breast cancer AND (neoadjuvant OR neo-adjuvant OR pre-operative OR preoperative OR induction) AND (clinical trial OR randomized controlled trial OR random OR randomized) AND (tamoxifen OR anastrozole OR exemestane OR letrozole OR aromatase inhibitors OR fulvestrant OR aromatase inhibitors OR fulvestrant OR antiestrogens”)”. Further selection was made by choosing “clinical trials” and “last 10 years” in the PubMed database filters. The remaining articles were singly evaluated for pertinence to our objectives.

Exclusion Criteria

In vitro experiments and animal studies were excluded. Trials that assessed only toxicity (phase I studies) or that included chemotherapy agents in the treatment plan were also excluded.

Response Evaluation

All the studies described herein evaluated clinical response after the neoadjuvant treatment [38-46]. Breast palpation, ecography or mammography were arbitrarily utilized. If not otherwise indicated we refer response to caliper measurements. The clinical response was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) [38, 40, 43 46] or the Union International Centre Cancer (UICC)
criteria [39, 41, 44, 45]: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). One study did not provide the evaluation criteria [42].

Results

The trial selection algorithm is illustrated in Fig. 1. Pubmed database showed a list of 476 articles. Many of them (225) were excluded for the lack of a clinical trial design. In order to focus on the most active endocrine agents currently used in the treatment of breast cancer, we limited the research to the last 10 years. Of the 119 articles resulted by the above restrictions, only 9 dealt with objective response rate (RR) [38-46]. As shown in Table 1, all papers were phase II studies, 4 randomized and 5 non-randomized, incorporating an AI as endocrine agent. In one study fulvestrant was used as well [40]. The table summarizes the types of agent investigated, the period of treatment and the clinical response observed in the studies. The targeted agents utilized in combination with AIs included inhibitors of TKRs, such as gefitinib [38-40], imatinib [41], or trastuzumab/lapatinib [42]; inhibitors of mTOR, such as everolimus [43]; inhibitors of Cox-2, such as celecoxib [44, 45]; inhibitors of angiogenesis, such as bevacizumab [46]. The details of the studies, with particular regard to clinical response, are described below.

| Study                  | R | N  | Period (weeks) | Clinical Response (%) |
|------------------------|---|----|----------------|-----------------------|
| Polychronis 2005 [38]  |   |    |                |                       |
| Gefitinib              | 29| 4-6| 17             | 62 10 0               |
| Gefitinib + ANA        | 27| 4-6| 26             | 41 26 0               |
| Smith 2007 [39]        |   |    |                |                       |
| ANA                    | 85| 16 | 4              | 57 33 4               |
| ANA + Gefitinib        | 31| 16 | 7              | 40 37 5               |
| Massarweh 2011 [40]   | No|    | 12             | 16 17 25 42 17       |
| ANA + Fulvestrant + Gefitinib | No|    | 10             | 12 90 10 0           |
| Choo 2008 [41]         |   |    |                |                       |
| LET + Imatinib         | 10| 12 | 0              | 90 0 10 0             |
| Rimawi 2013 [42]      |   |    |                |                       |
| LET + Trastuzumab + Lapatinib | 39| 12 | 46             | 54 0                  |
| Baselga 2009 [43]     |   |    |                |                       |
| LET                    | 138| 16 | 9.1            | 50 29.5 9.8           |
| LET + Everolimus      | 132| 16 | 13             | 55.1 24.6 4.3        |
| Choo 2008 [44]        |   |    |                |                       |
|EXE + Celecoxib        | 30| 12 | 10             | 48.6 40.5 0          |
|EXE                    | 24| 12 | 4              | 50.5 45.0 0          |
|Letrozole              | 28| 12 | 2              | 60 38.0               |
| Lustberg 2011 [45]    | No|    |                |                       |
| EXE → EXE + Celecoxib | 22| 8 8| 0              | 36 55 5              |
| Forero-Torres 2010 [46]| No|    |                |                       |
| LET + Bevacizumab     | 25| 24 | 16             | 52 16 8              |

AIs aromatase inhibitors, ANA anastrozole, LET letrozole, EXE, exemestane, R randomized study, N number of patients, CR complete response, PR partial response, SD stable disease, PD progressive disease.

The second study [39] randomized 236 women and provided similar results, reporting RRs of 47% and 61% in the combination group (121 patients) and anastrozole alone group (85 patients), respectively. However, the primary endpoint of the study was the change of Ki67 evaluated in tumor core biopsy after 2 weeks and after 16 weeks of treatment. The authors hypothesized that lack of Ki67 reduction after 2 weeks could identify patients whose tumor was resistant to anastrozole and that might be particularly sensitive to the added gefitinib. For this reason the combination group was divided into a group of patients receiving gefitinib 250 mg daily for 16 weeks and a group receiving placebo for 2 weeks, followed by gefitinib 250 mg daily for 14 weeks. The study failed to demonstrate any gefitinib-related difference in both Ki67 reduction and RR.
The third study [40] examined the activity of gefitinib 250 mg daily associated with a potential more effective endocrine treatment combining anastrozole 1 mg daily and fulvestrant 250 mg intramuscular monthly for 16 weeks. The study enrolled 15 patients, 3 of whom withdrew before response assessment. In the remaining 12 patients, RR was only 37%. Rate of pCR was not reported.

Imatinib, a potent inhibitor of PDGFR and cKit, was studied in combination with letrozole in a pilot study enrolling 13 women [41]. Patients received preoperatively imatinib 400 mg twice daily and letrozole 2.5 mg daily for 3 months. Three patients withdrew after 8 weeks because of hematoma in tumor or toxicity. Nine out of 10 evaluable patients (90%) obtained a PR and 1 (10%) had SD. One patient (10%) achieved a pCR.

The dual block of HER2, obtained with trastuzumab and lapatinib, was studied in 64 patients with locally advanced HER2-positive breast cancer [42]. Patients received trastuzumab weekly (4 mg/kg loading, then 2 mg/kg) and lapatinib 1000 mg daily for 12 weeks. Thirty-nine patients whose tumors were HR-positive were also treated with letrozole 2.5 mg daily. The study primary endpoint was the rate of pCR, which was 18% in the HR-positive group and 28% in the HR-negative group. No data were reported for clinical response, except for a table showing a RR (referred to as non-pCR) of 46% in the letrozole group. Moreover, given that only two patients experienced progression during the study treatment and both were in the HR-negative group, we can extrapolate that 54% of patients in the letrozole group had SD.

Inhibitors of mTOR

A phase II, randomized, double-blind, placebo-controlled trial was carried out to evaluate the rate of tumor response combining everolimus and letrozole in the neoadjuvant treatment of postmenopausal women with HR-positive breast cancer [43]. One hundred thirty-eight patients received letrozole 2.5 mg plus everolimus 10 mg daily, while 132 received letrozole plus placebo. Treatment was administered for 16 weeks. The RRs were 68.1% in patients treated with everolimus and 59.1% in patients treated with placebo (p=0.062), a difference considered statistically significant in the one-sided χ² test. Moreover, the combination arm showed a higher proportion of Ki67 index reduction (57% vs 30%, p<0.01). As expected, the everolimus group had a higher incidence of grade 3 and 4 toxicity compared with the placebo one (22.6% vs 3.8%), and a dose reduction or interruption was required in 52.9% of cases (vs 7.6% in the placebo treated patients). A pCR was reported in two patients treated with everolimus and in one treated with placebo.

Inhibitors of COX-2

We found two trials combining AIs with celecoxib, a cyclooxygenase-2 (COX-2) inhibitor. The first study [44] randomized 82 patients into 3 groups: group A (30 patients) received exemestane 25 mg daily and celecoxib 400 mg twice daily, group B (24 patients) received exemestane 25 mg daily, group C (28 patients) received letrozole 2.5 mg daily. The overall RRs were 58.6% for group A, 54.5% for group B and 62.0% for group C. No significant differences were observed among the three groups, but the combination group included 20% of patients with HER2-positive disease, a molecular phenotype expressed in only 7% and 8% of patients of group B and C, respectively. Moreover, group A showed the highest clinical CR (10%). A pCR was observed only in two (7%) patients of group C.

In the second study [45] 22 postmenopausal women were enrolled and treated with neoadjuvant exemestane 25 mg daily for 8 weeks, followed by exemestane 25 mg daily and celecoxib 400 mg twice daily for 8 weeks. The study had this design because its primary objective was the assessment of changes in the expression of the aromatase enzyme, as well as estrogen receptor, progesterone receptor, HER2, Ki67, and COX-2 in the tumor before, during, and after treatment. The study showed that progesterone receptor and Ki67 significantly decreased, by effect of the AI alone (8 weeks) and continued to reduce during combination therapy; estrogen receptor and COX-2 decreased only after combination therapy (16 weeks); HER2 and aromatase enzyme were not affected by treatment. The RR, evaluated at the end of treatment, was 36%. No patient obtained a clinical CR or pCR.

Inhibitors of angiogenesis

A single-arm pilot study was carried out to assess the activity of the combination of letrozole and bevacizumab, a monoclonal antibody inhibiting VEGF, in the neoadjuvant treatment of postmenopausal women with HR-positive breast cancer [46]. Twenty-five patients received letrozole 2.5 mg daily and intravenous bevacizumab 15 mg/kg every 3 weeks. An objective clinical response was observed in 17 of 25 patients (68%), with 4 CR (16%) and 13 PR (52%). Three out of 4 clinical CR were also pCR (12%).

Discussion

We performed a systematic literature review aimed at assessing if the addition of targeted agents might overcome endocrine resistance and improve clinical response in women with a recent diagnosis of
breast cancer treated preoperatively with endocrine therapies. To evaluate the anti-tumor activity of the investigated treatment we focused on clinical response rather than pCR because of the low pCR rate achieved with endocrine therapy, especially in a short-term treatment.

We found 9 articles that fulfilled the research criteria. All of them were phase II studies that utilized third generation AIs, in one study combined with fulvestrant, as endocrine agents. Historically, in the neoadjuvant setting, patients treated with AIs achieve RRs ranging between 37% and 70% [18-21]. In the impossibility to make a rigorous meta-analysis of the selected studies, due to small sample size, different duration of treatment and different types of targeted agents, and with the limitations inherent in phase II trials to provide valid conclusions due to selection and confounding biases, we speculate that 70% might be set as a reasonable RR threshold required to presume a clinical benefit of the combination therapy. In our clinical practice we obtained even a higher RR (86%) with neoadjuvant AIs [47].

Overall, the selected studies failed to demonstrate an advantage with added targeted agents over AIs alone. Figure 2 provides an overview of the RR obtained in each trial, and shows how much this value differs from the expected RR (shaded area). It is clear that in all studies but one, RR is within the estimated range, i.e. no advantage. The only study showing an impressive increase of response was the one combining letrozole and imatinib (RR 90%) [41]. However, the study has a very small sample size (10 patients evaluable for response) to allow any firm conclusion. Notably, in this study three patients withdrew for toxicity: one patient developed tumor hematoma and underwent surgery prematurely, two patients experienced acute coronary syndrome and generalized edema. If we recalculate RR on the “intention to treat” population rather than on the evaluable patients, it decreases to 69%, i.e. in the range of no benefit. However, the high RR observed combining imatinib and AI suggests further investigation, advisably with a dose less than 400 mg twice daily (the dose administered in the study), to reduce the potential risk of severe toxicity.

The overall unsatisfactory results observed adding preoperatively targeted agents to AIs is quite surprisingly considering the plethora of preclinical studies and the encouraging results in metastatic patients that indicate a synergistic effect. We try to argue possible explanations.

First, except for the study on trastuzumab/lapatinib [42] and one study on gefitinib [38] in which the expression of HER2 and EGFR in tumor tissue were evaluated, respectively, the targeted agents were utilized without patient selection for a specific molecular target. It is evident that only tumors expressing the functionally altered molecule (the target) might respond to the treatment. Moreover, it is likely that even when a target is identified and the right population selected to be treated, only a proportion might receive a benefit because of unknown co-existing molecular alterations that retain tumor resistance. Therefore, in a heterogeneous population of HR-positive breast cancer it is conceivable that small dimensioned phase II studies might fail their primary endpoint.
matase activity have been observed in breast cancer [51, 52]. However, the contribution of tumor synthesized estrogens to the breast cancer estrogen levels is negligible compared to systemic production. Intratumoral estrogens come mainly by circulatory uptake and, therefore, reflect plasma estrogen concentration [53]. For this reason reducing local estrogen synthesis could be not effective.

Finally, the duration of treatment might be too short. It has been reported that the longer is the neoadjuvant endocrine treatment the higher is the overall RR [54]. Rimawi et al. (S. Antonio 2014) showed that longer treatment with dual anti-HR2 therapy (trastuzumab plus lapatinib) in combination with endocrine therapy and without chemotherapy leads to a meaningful increase in pCR rate in HR+/HER2+ breast cancer (33% with 24 weeks vs 9% with 12 weeks of therapy) [55]. In most of the presented studies, patients were treated for no more than 4 months, and in some cases for just a few weeks.

Furthermore, RR might not be the only indicator of efficacy, especially for long-term outcome. Parameters such as Ki67 reduction, depth of response, or achievement of pCR could be relevant in regimens containing targeted agents. A significant reduction in Ki67 was observed adding gefitinib [38] or everolimus [43] to AI. Moreover, high rates of pCR were reported using AI with trastuzumab/lapatinib or bevacizumab, 18% and 13% respectively. This is particularly impressive for a nonchemotherapy-containing regimen, considering that hormone therapy alone rarely achieves pCR [56-58]. At the moment we do not know if the higher rates of Ki67 reduction or pCR observed with these targeted therapies might translate in a better clinical outcome.

In conclusion, thus far, in the breast cancer neoadjuvant setting, the attempts to increase endocrine response by targeting specific intracellular pathways have been disappointing. Further studies are needed for a better knowledge of the complex mechanisms responsible for “de novo” or acquired hormone resistance. The identification of a specific molecular target and a strict selection of HR-positive patients to treat are still the future challenge to improve endocrine responsiveness.

Abbreviations

AI: aromatase inhibitor; BCS: breast conserving surgery; CR: complete response; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor receptor 2; HR: hormone receptor; mTOR: mammalian target of rapamycin; PD: progressive disease; pCR: pathologic complete response; PDGF: platelet-derived growth factor receptor; PR: partial response; RR: response rate; SD: stable disease; TKR: tyrosine kinase receptor; VEGF: vascular endothelial growth factor.

Acknowledgments

This work was supported from the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) and institutional funding from ‘G. D’Annunzio’ University.

Competing interests

The authors declare that they have no competing interest.

References

1. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeece MD, Paulus D, Hug V, Holmes FA, Rosmdahl MM, Fraschini G, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988; 62:2043-16.
2. Danforth DN Jr, Lippman ME, McDonald H, Rader J, Egan E, Lampert M, Steinberg SM, Swain SM. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg. 1990; 56:6-11.
3. Schwartz GF, Birchsahns CA, Komarnicki LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane J. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994; 73:362-69.
4. Fisher B, Brown A, Mamounas E, Wirand S, Robidoux A, Margolese RG, Cruz AB, Jr., Fisher ER, Wickerham DL, Wolmarn N, DeCillis L, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15:2483-93.
5. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2011; 29:2244-37.
6. Semiglavov Z, Eiermann W, Vamti T, Manikas H, Bozhak A, Luch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeoAdjuvant HercepLImo (NOAH) study. Eur J Surg Oncol. 2011; 37:856-63.
7. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:188-94.
8. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahn ebergen MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24:2019-27.
9. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007; 94:1189-200.
10. Kroeger HM, Newman IA, Smith TL, Ames FC, Hurtt KK, Dhingra K, Theriault RL, Singh G, Binklely SM, Seege N, Buchholz TA, Ross MI, McNeese M, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17:460-9.
11. Kaufmann M, Hortobagyi GN, Goldhirsh A, Scholl S, Marias K, Valagussa P, Blohmer JU, Eiermann W, Jackes R, Jonat W, Lebeau A, Loibl S, Miller W, Seebier S, Semiglavov Z, Smith R, Souchon R, Shears V, Uchitake T, von Minckwitz G. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006; 24:1940-9.
12. Collette M, Bagnardi V, Rotmensz N, Gelber RD, Viade G, Prunier G, Veronesi P, Torrisi R, Cardillo A, Moretta E, Campagnoli E, Luiuia A, Intria M, Galimberti V, Scarano E, Peruzotti G, Goldhirsh A. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009; 116:359-70.
13. Huaber J, von Minckwitz G, Denkert C, Tesch H, Weihs E, Zahm DM, Belau A, Khandan F, Hauschuld M, Thomsen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S. Effect of neoadjuvant anthracycine-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010; 124:153-40.
14. Precht LM, Lowe KA, Atwood M, Beatty JD. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J. 2010; 16:362-68.
15. Strawer ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, van Zanen Peeters MT. The relevance of breast
cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010; 17:2411-18.

16. Kim SJ, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally ad- vanced breast cancer. Oncology. 2010; 79:234-30.

17. von Minckwitz G, Untch M, Blohmmer JU, Costa SD, Eidmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny G, Rehder DF, Denkert C, Middlentun S, Mehta K, Lofft S. Definition and impact of a pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30:1796-804.

18. Eiermann W, Paepeke S, Applested J, Lienhart-Cussac A, Eremijn J, Vinholso J, Juul F, Ellis M, Lassus C, Chaudry-Ross HA, Dugan M, Borg M. Pre- operative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001; 12:1357-32.

19. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmmer JU, Ashley SE, Feltkamp VW, Boedhorz J, Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preneoadjuvante Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005; 23:3537-44.

20. Catallozi L, Buzdar AU, Noguchi S, Bines J, Takataaka Y, Petronakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preope- rative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ Compared to Tamoxifen (PORT-C) trial. Cancer. 2010; 126:2095-103.

21. Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yangita N, Yishi- mura R, Iwase H, Kamigaki S, Takeh N, Noguchi S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012; 13:345-52.

22. Nicholson RJ, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine. 2004; 23:87-97.

23. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res. 2005; 11:899s-9a.

24. Bown CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24:85-95.

25. Price RS, Arbleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Slivkovski MX, Slamom DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995; 10:2455-46.

26. Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic re- sistance to aromatase inhibitors. Clin Cancer Res. 2006; 12:1008s-12s.

27. Grasso Sanon A, Lipici S, Noccioli S, Tavolotta S, Politi R, Ange- luci D, Marinelli C, Zilli M, Ausili Cefaro G, Tinari N, De Tursi M, Iezzi L, Ciotoli F, Iacobelli S, Natoli C, Cianni E. Long-term outcome of neoadjuvant endocrine therapy with anastrozole in endocrine-resistant breast cancer. Breast. 2010; 10:275-80.

28. Carvalho I, Milanesi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with clinical outcomes. Breast Cancer Res Treat. 2005; 97:287-95.

29. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt phosphorylation restores tamoxifen resistance and prevents development of resistance in breast cancer in vitro. Endocrinology. 2003; 144:5105-17.

30. Grassadonia A, Di Nicola M, Grossi S, Noccioli V, Tavolotta S, Politi R, Ange- luci D, Marinelli C, Zilli M, Ausili Cefaro G, Tinari N, De Tursi M, Iezzi L, Ciotoli F, Iacobelli S, Natoli C, Cianni E. Long-term outcome of neoadjuvant endocrine therapy with anastrozole in endocrine-resistant breast cancer. Breast. 2010; 10:275-80.

31. Godlewski J, Semiglavc V, van Dam P, Manikhas A, Bellet M, Maydome J, Campone M, Kubista E, Greil R, Bianchi G, Steines J, Molloy B, Tokaji E, Gardner H, Phillips R, Stamm B, Layman RM, Brugegmeier RW, Shapiro CL. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer. 2011; 11:221-7.

32. Chow LW, Loy AY, Loo WT, Toi M. Celecoxib anti-aromatase neo-adjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol. 2008;11:11-17.

33. Lustberg MB, Vopposki SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AAS, Lehman AM, Shiel DR, Mrozek E, Ramassamy B, Layman RM, Brugegmeier RW, Shapiro CL. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27:3630-7.

34. Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent JJ, Nabell LM, Carpenter JT, Falkson CL, Krontrias H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Carterina V, Bremeren Wu, O’Malley JP, L. LoBuglio AF. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen re- sponse- or progesterone receptor-positive breast cancer. Clin Breast Cancer. 2011; 14:35-43.

35. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome pro- liferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer. 2003; 103:84-90.

36. Bruguera M, Quinn E, Parrett ML, Joarder FS, Harris AL, Robertson LM, Allevi G, Strina C, Andreis D, Petronini PG. Overcoming acquired resistance to letro- zole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012; 323:77-87.

37. Chow LW, Jesgas SY, Jasm J. Phase 3 study of temsirolimus with letrozole or placebo alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006; 100(suppl 1):abstr691.

38. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brichet S, Chow L, Sun Y, Novske-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strabs A, Cincotta A, Krygowski A, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in women with hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2011; 129:1893-7.

39. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer. 2003; 103:84-90.

40. Catm et al., Yilmaz MF, Rezvani HH, Joarder FS, Harris AL, Robertson LM, Allevi G, Strina C, Andreis D, Petronini PG. Overcoming acquired resistance to letro- zole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012; 323:77-87.

41. Chow LW, Jesgas SY, Jasm J. Phase 3 study of temsirolimus with letrozole or placebo alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006; 100(suppl 1):abstr691.
treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer. 2013; 108:1587-92.

55. Rimawi MF, Niravath PA, Wang T, et al. TBCRC023: A randomized multi-center phase II neoadjuvant trial of lapatinib plus trastuzumab, with endocrine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. San Antonio Breast Cancer Symposium (SABCS) 2014; S6-02.

56. Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Grant M, Reiner A, Teleyk B, Seitz W, Jakesz R. It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. Breast Cancer Res Treat. 1998; 53:37-46.

57. Berruti A, Generali D, Kaufmann M, Pusztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, et al. An international expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011; 2011:147-51.

58. Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Luca G. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012; 132:843-51.